PURPOSE: Subsartorial saphenous nerve blockade (SSNB) is an effective analgesic alternative to femoral nerve blockade after anterior cruciate ligament (ACL) reconstruction with bone-tendon-bone (BTB) autograft. It was hypothesized that dexamethasone in a SSNB will prolong analgesia, improve pain and satisfaction, and reduce postoperative opioid requirements and side effects. METHODS: One hundred ninety-five patients undergoing ACL reconstruction with BTB autograft (ages 16-65) were enrolled. Subjects received SSNB with 13 ml of 0.5 % bupivacaine (control group), 1 mg preservative-free dexamethasone +0.5 % bupivacaine (treatment group I), or 4 mg preservative-free dexamethasone +0.5 % bupivacaine (treatment group II). Subjects received identical perioperative management. On postoperative days 1 and 2, subjects reported perceived block duration, pain scores, satisfaction, opioid use, and side effects. Cox-proportional hazards modelling was used to compare block duration, adjusting for body mass index, age, sex, tourniquet time, American Society of Anesthesiologists classification, and intravenous dexamethasone dose. RESULTS: Patient-perceived block duration was significantly increased in treatment group I [hazard ratio (95 % confidence interval [CI]) 0.48 (0.31-0.75); P = 0.001] and treatment group II (hazard ratio (95 % CI): 0.52 (0.33-0.81); P = 0.004) compared to control. The block was extended from a median (95 % CI) of 33.1 (28.4-37.3) to 41.2 (32.4-50.9) and 46.5 (35.8-48.9) hours, respectively. Additionally, patients in treatment group II reported increased time that block provided pain relief, higher patient satisfaction, lower pain scores at rest, and decreased drowsiness and confusion. CONCLUSION: The addition of 1 and 4 mg of dexamethasone to the block injectate significantly increased SSNB duration by 8-13 h compared to control. LEVEL OF EVIDENCE: Therapeutic study, level 1.
PURPOSE: Subsartorial saphenous nerve blockade (SSNB) is an effective analgesic alternative to femoral nerve blockade after anterior cruciate ligament (ACL) reconstruction with bone-tendon-bone (BTB) autograft. It was hypothesized that dexamethasone in a SSNB will prolong analgesia, improve pain and satisfaction, and reduce postoperative opioid requirements and side effects. METHODS: One hundred ninety-five patients undergoing ACL reconstruction with BTB autograft (ages 16-65) were enrolled. Subjects received SSNB with 13 ml of 0.5 % bupivacaine (control group), 1 mg preservative-free dexamethasone +0.5 % bupivacaine (treatment group I), or 4 mg preservative-free dexamethasone +0.5 % bupivacaine (treatment group II). Subjects received identical perioperative management. On postoperative days 1 and 2, subjects reported perceived block duration, pain scores, satisfaction, opioid use, and side effects. Cox-proportional hazards modelling was used to compare block duration, adjusting for body mass index, age, sex, tourniquet time, American Society of Anesthesiologists classification, and intravenous dexamethasone dose. RESULTS:Patient-perceived block duration was significantly increased in treatment group I [hazard ratio (95 % confidence interval [CI]) 0.48 (0.31-0.75); P = 0.001] and treatment group II (hazard ratio (95 % CI): 0.52 (0.33-0.81); P = 0.004) compared to control. The block was extended from a median (95 % CI) of 33.1 (28.4-37.3) to 41.2 (32.4-50.9) and 46.5 (35.8-48.9) hours, respectively. Additionally, patients in treatment group II reported increased time that block provided pain relief, higher patient satisfaction, lower pain scores at rest, and decreased drowsiness and confusion. CONCLUSION: The addition of 1 and 4 mg of dexamethasone to the block injectate significantly increased SSNB duration by 8-13 h compared to control. LEVEL OF EVIDENCE: Therapeutic study, level 1.
Authors: Rohit Rahangdale; Mark C Kendall; Robert J McCarthy; Luminita Tureanu; Robert Doty; Adam Weingart; Gildasio S De Oliveira Journal: Anesth Analg Date: 2014-05 Impact factor: 5.108
Authors: Mary F Chisholm; Heejung Bang; Daniel B Maalouf; Dorothy Marcello; Marco A Lotano; Robert G Marx; Gregory A Liguori; Victor M Zayas; Michael A Gordon; Jason Jacobs; Jacques T YaDeau Journal: HSS J Date: 2014-06-07
Authors: Jiabin Liu; Kenneth A Richman; Samuel R Grodofsky; Siya Bhatt; George Russell Huffman; John D Kelly; David L Glaser; Nabil Elkassabany Journal: J Clin Anesth Date: 2015-01-28 Impact factor: 9.452
Authors: Faraj W Abdallah; James Johnson; Vincent Chan; Harry Murgatroyd; Mohammad Ghafari; Noam Ami; Rongyu Jin; Richard Brull Journal: Reg Anesth Pain Med Date: 2015 Mar-Apr Impact factor: 6.288
Authors: Jacques T Yadeau; Spencer S Liu; Matthew C Rade; Dorothy Marcello; Gregory A Liguori Journal: Anesth Analg Date: 2011-04-27 Impact factor: 5.108
Authors: M Desmet; H Braems; M Reynvoet; S Plasschaert; J Van Cauwelaert; H Pottel; S Carlier; C Missant; M Van de Velde Journal: Br J Anaesth Date: 2013-04-15 Impact factor: 9.166
Authors: Ed Carlos Rey Moura; Caio Marcio Barros de Oliveira; Plinio da Cunha Leal; Rioko Kimiko Sakata Journal: J Pain Res Date: 2021-01-13 Impact factor: 3.133